Liprolog Mix50 (Insulin Lispro)

Liprolog Mix50, a rapid‑acting insulin analog, is used to manage hyperglycaemia in diabetes mellitus.

• Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces risk of hyperglycaemic episodes.
• Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with oral agents or basal insulin.

• Insulin lispro binds to insulin receptors on muscle and adipose cells, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling that moves GLUT‑4 transporters to the cell surface, increasing glucose uptake. In the liver it suppresses gluconeogenesis and glycogenolysis, lowering circulating glucose. Its rapid dissociation from hexameric complexes provides a quicker onset of action than regular human insulin.

Liprolog Mix50 may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Hypoglycaemia: low blood glucose levels, often presenting with sweating, tremor, or confusion.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Lipodystrophy: localized changes in subcutaneous fat tissue.
• Weight gain: modest increase in body weight over time.

Serious or Rare Side Effects

• Severe hypoglycaemia: prolonged loss of consciousness or seizures.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Lipohypertrophy with repeated injections causing large fatty deposits.

When prescribing Liprolog Mix50, clinicians should consider several safety measures to minimise risks.

• Dose adjustment: tailor the insulin dose to individual carbohydrate intake and blood glucose monitoring.
• Hypoglycaemia risk: educate patients on recognising and treating low blood glucose promptly.
• Renal impairment: monitor kidney function and adjust dose if necessary.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with other medicines, altering its glucose‑lowering effect or increasing adverse events.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycaemia symptoms, requiring closer monitoring.
• MAO‑B inhibitors (e.g., selegiline): can potentiate insulin’s hypoglycaemic effect.

Moderate Interactions (Monitor Closely)

• Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect may increase hypoglycaemia risk.
• Corticosteroids: may raise blood glucose, necessitating dose adjustments.
• Thiazide diuretics: can impair glucose tolerance, requiring closer glucose monitoring.